- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01110031
Ofatumumab Cardiac Repolarization (QTc) Study in Fludarabine-Refractory Chronic Lymphocytic Leukemia Subjects
November 8, 2017 updated by: GlaxoSmithKline
An Open-Label, Single-Arm, Phase I Study to Evaluate the Effect of Ofatumumab on Cardiac Repolarization (QTc Duration) in Patients With Fludarabine-Refractory B-cell Chronic Lymphocytic Leukemia
Ofatumumab is a fully-human monoclonal antibody that exhibits high binding affinity to an antigen on the surface of B lymphocytes.
Antigen engagement by ofatumumab results in maximal B-cell killing through complement-dependent cytotoxicity and antigen-dependent cellular cytotoxicity in both antigen high- and low-expressing cells.
Recent research has shown that ofatumumab-dependent B-cell depletion provides clinical benefit to subjects with CD20-positive cancers such as chronic lymphocytic leukemia (CLL).
The purpose of the current study is to assess the impact of ofatumumab on electrocardiographic parameters with particular focus on cardiac repolarization (QTc interval duration) in subjects with refractory CLL.
Subjects enrolled in this open-label, single-arm trial will receive ofatumumab at the highest clinical dose (2000 mg) studied or planned for study.
Ofatumumab will be administered as eight weekly intravenous (IV) infusions followed by four monthly infusions, beginning in Week 13, across a 25-week treatment period.
Cardiovascular effects will be evaluated during treatment through routine 12-lead electrocardiographic (ECG) monitoring.
The pharmacokinetic relationship between plasma concentration of ofatumumab and its effect on QTc interval duration will be examined.
Specifically, ECG assessments will be collected in triplicate at baseline, at the time of maximum ofatumumab concentrations periodically on-therapy, and at the end of treatment.
After completion of the final ofatumumab infusion, subjects will continue to be followed for safety and efficacy for six months relative to the last ofatumumab dose.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Detailed Description
The purpose of this trial is to assess the impact of ofatumumab on electrocardiographic parameters with particular focus on cardiac repolarization (QTc interval duration) in subjects with refractory Chronic Lymphocytic Leukemia (CLL).
Study Type
Interventional
Enrollment (Actual)
12
Phase
- Phase 1
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
New South Wales
-
Randwick, New South Wales, Australia, 2031
- GSK Investigational Site
-
-
-
-
-
Auckland, New Zealand, 1150
- GSK Investigational Site
-
Christchurch, New Zealand, 8011
- GSK Investigational Site
-
-
-
-
California
-
La Jolla, California, United States, 92093
- GSK Investigational Site
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Confirmed diagnosis of Chronic Lymphocytic Leukemia (CLL).
- Active CLL disease and indication for treatment.
- Previous treatment with fludarabine-containing treatment that did not achieve at least a partial response or, disease progression occurred in responders within six months of the last dose of a fludarabine-containing treatment regimen.
- Fully active at a minimum, or fully capable of self-care and up and about more than 50% of waking hours.
- Age 18 years or older.
- Signed written informed consent.
- Acceptable levels of laboratory chemistry tests of potassium and magnesium.
- Males and female subjects must agree to use contraception (if fertile) from the time of the first dose of study medication until one year following last dose of ofatumumab.
Exclusion Criteria:
- Any abnormal electrocardiogram (ECG) or cardiac conduction findings .
- Certain heart problems, chronic infections, or serious significant diseases.
- Known transformation of CLL.
- CLL central nervous sytem involvement.
- Abnormal/inadequate blood values, liver, or kidney function.
- Past or current malignancy besides CLL, unless you have been free of malignancy for at least two years, have a history of completely resected non-melanoma skin cancer, or have been successfully treated.
- Lactating women or women with a positive pregnancy test.
- Use of medications known to prolong the heart rhythm.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Other
- Allocation: Non-Randomized
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Treatment
Six months treatmet with ofatumumab will be given to subjects with chronic lymphocytic leukemia.
|
Anti-CD20 monoclonal antibody
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Cardiac Repolarization (Fredericia's QTc)
Time Frame: 25-week ofatumumab treatment period
|
ECGs are collected in triplicate during the study to assess QTc effect.
|
25-week ofatumumab treatment period
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Plasma concentrations of ofatumumab and electrocardiogram (ECG) parameters
Time Frame: 25-week ofatumumab treatment period
|
The pharmacokinetic results will be correlated to ECG findings to determine if drug concentrations relate to any ECG effects.
|
25-week ofatumumab treatment period
|
Vital signs, weight, adverse events
Time Frame: 25-week ofatumumab treatment period plus 6-month follow-up after final ofatumumab infusion
|
Safety and tolerability of ofatumumab therapy will be determined by analysing changes in vital signs, weight, or development of adverse events.
|
25-week ofatumumab treatment period plus 6-month follow-up after final ofatumumab infusion
|
Flow cytometry
Time Frame: 25-week ofatumumab treatment period plus 6-month follow-up after final ofatumumab infusion
|
Efficacy of ofatumumab therapy will be measured by the number of CD20 positive cells in the blood
|
25-week ofatumumab treatment period plus 6-month follow-up after final ofatumumab infusion
|
Cytokine, chemokine, human anti-human antibodies
Time Frame: 25-week ofatumumab treatment period plus 6-month follow-up after final ofatumumab infusion
|
Effect of ofatumumab on circulating biomarkers in refractory Chronic Lymphocytic Leukemia (CLL) subjects will be determined by measuring changes in the cytokine, chemokine, human anti-human antibody levels.
|
25-week ofatumumab treatment period plus 6-month follow-up after final ofatumumab infusion
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
May 13, 2010
Primary Completion (Actual)
April 12, 2012
Study Completion (Actual)
June 26, 2012
Study Registration Dates
First Submitted
April 22, 2010
First Submitted That Met QC Criteria
April 22, 2010
First Posted (Estimate)
April 23, 2010
Study Record Updates
Last Update Posted (Actual)
November 13, 2017
Last Update Submitted That Met QC Criteria
November 8, 2017
Last Verified
November 1, 2017
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 112855
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Leukaemia, Lymphocytic, Chronic
-
AstraZenecaCLL ConsortiumCompletedB Cell Lymphomas | 11q-deleted Relapsed/Refractory Chronic Lymphocytic Leukaemia (CLL), | Prolymphocytic Leukaemia (PLL)United States
-
GlaxoSmithKlineCompletedLeukaemia, Lymphocytic, Chronic
-
GlaxoSmithKlineCompletedLeukaemia, Lymphocytic, ChronicKorea, Republic of, Japan
-
Novartis PharmaceuticalsCompletedChronic Lymphocytic Leukemia (CLL) | Leukaemia, Lymphocytic, ChronicUnited States, Belgium, Italy, Greece, Russian Federation, Spain, Poland, Czech Republic
-
GlaxoSmithKlineCompletedLeukaemia, Lymphocytic, ChronicJapan
-
GlaxoSmithKlineGenmabCompletedLeukaemia, Lymphocytic, ChronicSweden
-
Novartis PharmaceuticalsCompletedLeukaemia, Lymphocytic, ChronicIndia, United Kingdom, Netherlands, Canada, Germany, Greece, Italy, Poland, Russian Federation, Spain, Taiwan, Thailand, United States, Brazil, Bulgaria, Mexico, Romania, Ukraine
-
Novartis PharmaceuticalsTerminatedLeukaemia, Lymphocytic, ChronicSpain, United States, Belgium, India, United Kingdom, Netherlands, Czechia, Germany, Greece, Italy, Russian Federation, Sweden, Canada, Ireland, Poland, France, Brazil
-
Gilead SciencesCompletedChronic Lymphocytic LeukaemiaUnited Kingdom, Ireland
-
GlaxoSmithKlineCompletedLeukaemia, Lymphocytic, ChronicUnited States, United Kingdom
Clinical Trials on Ofatumumab
-
GlaxoSmithKlineTerminatedArthritis, RheumatoidUnited States, Denmark, Hungary, United Kingdom, Poland
-
GlaxoSmithKlineCompletedMultiple SclerosisUnited States, Bulgaria, Russian Federation, Spain, Germany, Czechia, Netherlands, Norway, Italy, Canada, Denmark
-
GlaxoSmithKlineCompleted
-
Novartis PharmaceuticalsCompleted
-
Fondazione Italiana Linfomi ONLUSCompletedFollicular Lymphoma, Grade 1 | Follicular Lymphoma, Grade 2 | Follicular Lymphoma Grade 3AItaly
-
Alliance for Clinical Trials in OncologyNational Cancer Institute (NCI)Completed
-
GlaxoSmithKlineCompletedLeukaemia, Lymphocytic, Chronic
-
GlaxoSmithKlineCompletedLeukaemia, Lymphocytic, Chronic and Lymphoma, FollicularJapan
-
Novartis PharmaceuticalsRecruitingMultiple Sclerosis (MS)France
-
Gruppo Italiano Malattie EMatologiche dell'AdultoActive, not recruitingLeukemia, Lymphoblastic, ChronicItaly